---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-24-000061"
form_type: "8-K"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2024-07-17T23:59:59+00:00"
generated_at: "2026-05-31T20:21:44.265710+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ligand completes acquisition of APEIRON Biologics for $100M cash plus up to $28M contingent

## Summary
- Ligand acquired all outstanding shares of APEIRON for $100M in cash at closing on July 15, 2024.
- Additional contingent consideration up to $28M if QARZIBA royalties exceed predetermined thresholds by 2030 or 2034.
- QARZIBA (dinutuximab beta) is approved for high-risk neuroblastoma; Ligand obtains royalty rights.
- Acquisition funded from Ligand's available cash on hand; closing subject to 30-day shareholder objection period.
- Deal structured as a definitive agreement first announced on July 8, 2024.

## SEC filing metadata
- accession: 0000886163-24-000061
- form_type: 8-K
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2024-07-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616324000061/0000886163-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616324000061/lgnd-20240715.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-24-000061
- JSON: https://secwatch.observer/filing/0000886163-24-000061.json
- Plain text: https://secwatch.observer/filing/0000886163-24-000061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.